HUTCHMED (China) (CHIX:HCML) Receivables Turnover: 1.99 (As of Dec. 2025)


CHIX:HCML HUTCHMED (China) Ltd CHIX:HCML
60 GF Score
Price £1.67
GF Value £2.24
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is HUTCHMED (China) Receivables Turnover?

HUTCHMED (China) CHIX:HCML 60 Receivables Turnover is 1.99 as of Dec. 2025. GuruFocus rates CHIX:HCML with a GF Score™ of 60/100 and a GF Value™ of £2.24 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 950 Drug Manufacturers companies, HUTCHMED (China) ranks worse than 69.89% on this metric.

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. HUTCHMED (China)'s Revenue for the six months ended in Dec. 2025 was £202.3 Mil. HUTCHMED (China)'s average Accounts Receivable for the six months ended in Dec. 2025 was £101.5 Mil. Hence, HUTCHMED (China)'s Receivables Turnover for the six months ended in Dec. 2025 was 1.99.


HUTCHMED (China)  (CHIX:HCMl) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.


HUTCHMED (China) Receivables Turnover Related Terms


HUTCHMED (China) Receivables Turnover Historical Data

* Premium members only.

The historical data trend for HUTCHMED (China)'s Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HUTCHMED (China) Receivables Turnover Chart

HUTCHMED (China) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.44 4.89 7.66 4.63 3.76

HUTCHMED (China) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.48 2.23 2.08 1.77 1.99

CHIX:HCML vs ZTS, UTHR, VTRS: Receivables Turnover Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HUTCHMED (China) Receivables Turnover vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s Receivables Turnover distribution charts can be found below:

* The bar in red indicates where HUTCHMED (China)'s Receivables Turnover falls into.


CHIX:HCML
60GF Score
HUTCHMED (China) Ltd CHIX:HCML
Receivables Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HUTCHMED (China) Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

HUTCHMED (China)'s Receivables Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Receivables Turnover (A: Dec. 2025 )
=Revenue / Average Accounts Receivable
=Revenue (A: Dec. 2025 ) / ((Accounts Receivable (A: Dec. 2024 ) + Accounts Receivable (A: Dec. 2025 )) / count )
=409.738 / ((123.03 + 94.682) / 2 )
=409.738 / 108.856
=3.76

HUTCHMED (China)'s Receivables Turnover for the quarter that ended in Dec. 2025 is calculated as

Receivables Turnover (Q: Dec. 2025 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Dec. 2025 ) / ((Accounts Receivable (Q: Jun. 2025 ) + Accounts Receivable (Q: Dec. 2025 )) / count )
=202.314 / ((108.315 + 94.682) / 2 )
=202.314 / 101.4985
=1.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Receivables Turnover →
What does a Receivables Turnover of 1.99 mean?
HUTCHMED (China) (CHIX:HCML) has a Receivables Turnover of 1.99 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on HUTCHMED (China) and its competitors. According to the industry distribution chart, HUTCHMED (China) ranks #664 out of 950 companies in the Drug Manufacturers industry, placing it in the top 69.9%.
Is HUTCHMED (China)'s Receivables Turnover too high?
HUTCHMED (China)'s current Receivables Turnover is 1.99. The Drug Manufacturers industry median Receivables Turnover is 5.07. HUTCHMED (China)'s value of 1.99 is 60.7% below this industry median. Based on the distribution chart, HUTCHMED (China) ranks #664 out of 950 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, HUTCHMED (China) has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HUTCHMED (China) ranks #664 out of 950 companies for Receivables Turnover. This places HUTCHMED (China) in the lower half of its industry. The industry median Receivables Turnover is 5.07. HUTCHMED (China)'s value of 1.99 is 60.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HUTCHMED (China)'s current Receivables Turnover of 1.99 is 60.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on HUTCHMED (China) and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HUTCHMED (China)'s current Receivables Turnover is 1.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
Based on GuruFocus' analysis, HUTCHMED (China) (CHIX:HCML) is currently considered Modestly Undervalued. The stock's GF Value™ is £2.24, compared to a current price of £1.67 — trading 25.4% below its estimated fair value. The current Receivables Turnover is 1.99 and 60.7% below the Drug Manufacturers industry median of 5.07. HUTCHMED (China)'s overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For HUTCHMED (China) (CHIX:HCML), the current Receivables Turnover is 1.99 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HUTCHMED (China) (CHIX:HCML) Overvalued in 2026?

Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued. The current stock price of £1.67 is trading 25.4% below its estimated GF Value™ of £2.24. GuruFocus considers HUTCHMED (China) to be Modestly Undervalued.

Key valuation signals for CHIX:HCML:

  • Receivables Turnover: 1.99
  • GF Value™: £2.24 vs. price of £1.67 (25.4% below fair value)
  • GF Score™: 60/100 with 8 warning signs
  • Industry Position: 60.7% below the Drug Manufacturers median (#664 of 950)

No single metric tells the full story. See the CHIX:HCML stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HUTCHMED (China) Business Description

Address 2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
60GF Score

Get the complete analysis for CHIX:HCML

Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£1.67
Price
£2.24
GF Value